Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, named Michael Stocum as president and CEO.
The board of directors at Medivir AB tapped Magnus Christensen, the company’s chief financial officer, as interim CEO.
Biotech company Novavax Inc. promoted Gale E. Smith, Ph.D., to senior VP, discovery and pre-clinical research and chief scientist, and appointed Troy Morgan as senior VP, chief compliance officer.
Viome appointed Dr. Emmanuel Hanon as global head of research and development.
Kyverna Therapeutics chose James Chung, M.D., Ph.D., as the cell therapy company’s first chief medical officer.
Erin Pennock Foff, M.D., Ph.D., was named chief medical officer of the CNS company MapLight Therapeutics.
LogicBio Therapeutics Inc., a clinical-stage genetic medicine company, promoted Daniel Gruskin, M.D., to chief medical officer.
Capsida Biotherapeutics Inc. appointed Swati Tole, M.D., as the biotechnology company’s first chief medical officer.
Shaemus Gleason was appointed executive VP U.S. operations at Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease.
Irena Melnikova, Ph.D., was hired by Umoja Biopharma to be the biotechnology company’s new chief financial officer.
